Waters ACQUITY UPLC TQD system receives approval in China Waters announced that the Chinese Food and Drug Administration approved the registration of the ACQUITY UPLC TQD system for legal promotion and sale in China as a medical device for routine diagnostic applications and neonatal metabolites diseases screening.
News For WAT From The Last 14 Days
Check below for free stories on WAT the last two weeks.
Waters narrows FY14 EPS view to $5.25-$5.40 from $5.25-$5.50 Consensus is $5.31. Organic sales growth at or above mid single digit range. Sees mid-to-high single digit top line growth in 2H. Sees government funded instrument sales in the U.S. increasing in 2H. Says governmental spending in China beginning to improve. Sees sales growth in Q3, Q4 that would result in FY14 constant currency mid single digit growth. Says still working to find a successor to CEO Douglas Berthiaume. Sees FY operating tax rate 14%-15%. Sees currency neutral to sales growth in FY. Sees FY gross margins 58.5%-59%.